GHK-CU (Glycyl-L-Histidyl-L-Lysine-Copper) plays a vital role in wound healing, collagen synthesis, and skin elasticity
Rest between cycles: 2-4 weeks off after a full cycle before starting another
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Where it tends to fall behind is during periods of extra demand: chronic stress, frequent immune challenges, exposure to environmental toxins, or simply getting older, since glutathione status naturally tends to decline with age.* People who tend to be drawn to this product include those focused on liver and detox support, anyone who's tried a standard glutathione capsule and felt like nothing happened, and people who prefer liquid supplements over pills to begin with
Macrophages regulate the inflammatory process depending on their differentiation status
Each batch is characterised by reversed-phase HPLC (99%) and identity-confirmed by mass spectrometry
.png)
